Spectranetics Enrolls First Patient In PATENT Trial For The Treatment Of Instent Restenosis
Sep 28th 2007Drug InformationCardiovascular
Spectranetics Corporation (Nasdaq: SPNC) announced it has enrolled the first patient in the PATENT trial utilizing the Company’s TURBO elite(TM) laser catheters in combination with the recently FDA cleared TURBO-Booster(TM). The PATENT trial is a prospective registry of 100 patients at up to 10 sites in Germany. The trial will assess patency as measured by duplex ultrasound at various intervals up to 12 months following the procedure. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
